GREY:IMVIF - Post by User
Post by
Betteryear2on Dec 21, 2021 7:49am
140 Views
Post# 34249552
Finalization of the Basket Clinical Study
Finalization of the Basket Clinical Study
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and hematologic cancers, today announced the finalization of the basket clinical study evaluating maveropepimut-S (MVP-S, previously known as DPX-Survivac) in combination with Merck’s KEYTRUDA® in patients with metastatic bladder and Micro-Satellite Instability High (MSI-H) solid tumors.
https://www.businesswire.com/news/home/20211221005127/en/